We're not waiting for a cure.
We're powering it.
Twenty-five years building the infrastructure of a cure.
The science is ready. The community is ready.
A new chapter
The Hereditary Neuropathy Foundation is now CureCMT
Same foundation, same fight, a name that says exactly what we are here to do. Here is the story in 47 seconds.
Voices of CMT
Real life with CMT, straight from the community
Stay connected
Research news + community stories, in your inbox
Three ways to power the cure
Find your path
You're not alone.
Understand your diagnosis, find a specialist, and manage daily life with CMT.
Start here → Science and IndustryThe patient is the platform.
Access the world's most comprehensive CMT patient registry. Partner with TRIAD. Engage accredited clinical sites.
Partner with us → Support the CureAcceleration, not charity.
Your investment funds the infrastructure that gets therapies to patients faster.
Give now →Why HNF
Built to outlast the wait.
- Since 200125 years advancing CMT research
- GRIN registryopen to every CMT subtype (100+ genes identified to date)
- Convenedthe FDA's first Patient-Focused Drug Development meeting for CMT (2018)
- CMT biobankavailable to qualified researchers and industry leaders
- Venture philanthropypartnerships with biotech to accelerate CMT therapies
In partnership with researchers, clinicians, and industry worldwide
Before HNF, none of this existed.
- Global patient registry
- FDA patient dialogue
- Largest CMT biobank
- Digital biomarker tools
- Onsite summit research
HNF built all of it. First.
Join GRIN
Your Data. Your Cure.
Join GRIN, the Global Registry for Inherited Neuropathies. Your genetic data directly accelerates therapy development for your CMT subtype.
Join GRIN →News & Stories
Latest from HNF
A Sharper Signal: Could Hearing Be CMT’s Next Clinical Trial Endpoint?
CureCMT (HNF) brought hearing testing on-site at the 2026 Clinical Trial Readiness Summit, a first for the CMT community. About half of those screened showed some hearing loss, matching what 445 GRIN registry responses had been saying for years.
Read more → September 16, 2026“The Next Family Deserves Better”: CureCMT (HNF) Brings the CMT-SORD Community’s Voice to the FDA
On August 4, CureCMT (HNF) led a Patient-Focused Listening Session with the FDA dedicated entirely to CMT-SORD. Six patients and family members told the agency what the disease costs them, and what a treatment would give back.
Read more → May 21, 2026ENCell's EN001 Enters Phase 2a Trials for CMT1A
A South Korean biotech, ENCell, has dosed the first patient in a Phase 2a trial of EN001, a stem cell therapy aimed at the myelin damage behind CMT1A.
Read more →